Essentials
• Warfarin typically requires International Normalized Ratio (INR) testing at least every 4 weeks.
• We implemented extended INR testing for stable warfarin patients in six anticoagulation clinics.
• Use of extended INR testing increased from 41.8% to 69.3% over the 3 year study.
• Use of extended INR testing appeared safe and effective. [2] . Following an observational study demonstrating the safety of INR testing intervals up to 14 weeks, a single-center randomized trial demonstrated the safety and feasibility of an every 12-week versus an every 4-week INR testing interval for stable warfarin patients in 2011 [3, 4] . On the basis of this single-center trial, the American College of Chest Physicians provided a Grade 2B recommendation in favor of an every 12-week INR testing interval over an every 4-week INR testing interval for stable warfarin patients [5] . However, practice-based adoption has not been reported outside of a clinical trial setting [6] .
In 2014, six participating anticoagulation centers in the Michigan Anticoagulation Quality Improvement Initiative (MAQI 2 ) collaborative modified INR testing interval protocols to allow extended intervals for stable warfarin patients. Given the diversity of each clinic's patient population and structure, each clinic established its own definition of 'stable' warfarin patients and the maximum allowable INR testing interval. We explored the rate of extended INR testing interval utilization at each of these six anticoagulation services and the associated clinical outcomes.
Methods

MAQI 2
The MAQI 2 is a collaborative of six anticoagulation clinics sponsored by Blue Cross-Blue Shield of Michigan/ Blue Care Network to improve the quality of anticoagulation care in the state of Michigan [7] . A sample of patients who have started receiving warfarin for any indication are enrolled at each site, and all clinical interactions with the anticoagulation clinic or healthcare system, including laboratory values, are manually abstracted from the medical chart and entered into the MAQI 2 database by trained data abstractors. The abstracted data undergo random audits by the coordinating center team. Each of the centers participates in a number of quality improvement efforts, but all clinical care is provided by the anticoagulation staff (nurses and pharmacists) independently of the MAQI 2 research team. Data collection, research and quality improvement efforts have been approved by the Institutional Review Boards at the coordinating center (University of Michigan) and all participating sites.
Extended INR testing interval quality improvement effort
In 2014, a collaborative-wide quality improvement effort was initiated to allow for extended INR testing intervals for stable warfarin-treated patients. After review by the medical directors and clinic staff, each anticoagulation clinic established its own guidelines to determine which patients were deemed to be stable and eligible for an extended INR testing interval (Table 1) . Similarly, each clinic established the maximum INR testing interval that could be recommended for eligible patients, usually extending from a previous maximum of 4 weeks to a new maximum of 6 weeks or 8 weeks (specific to each clinic). Utilization rates of the extended INR testing interval (based on the assessment of nurse-recommended or pharmacist-recommended next INR test date) were provided to each center's nurse or pharmacist and physician leaders on a quarterly basis, with details about any patient who was eligible but not offered an extended INR testing interval. Clinically important outcomes, such as the percentage of next INRs that were out of range or extremely out of range, bleeding events, thromboembolic events, and emergency department (ED) visits, were reviewed quarterly with the anticoagulation clinic leadership teams.
Patient selection and outcomes
For this analysis, eligible patients with active warfarin prescriptions in 2014-2016 who met their individual center's definition of a stable warfarin patient (Table 1) were included. Patients were excluded if they regularly selftested the INR, had a left ventricular assist device in place, had evidence of chronic renal insufficiency documented in the medical chart problem list, or had previously refused any recommended extended INR testing intervals. At one site (Site 2), patients were also excluded if they had any history of bleeding, were eating foods with a high vitamin K content to help with warfarin dosing, or had antiphospholipid antibody syndrome. Similarly, patients who experienced an adverse clinical event (e.g. ED visit or bleeding event), underwent any medication change, temporarily stopped warfarin therapy (e.g. for a surgical procedure), developed a new comorbidity or were undergoing chemotherapy during an otherwise stable period were not included in the analysis, as most of the anticoagulation clinics would not have offered an extended INR testing interval in these situations. The primary outcome was the percentage of eligible patients who were scheduled for an extended INR testing interval (> 5 weeks; average of 6 weeks) at each participating center, assessed quarterly. Secondary outcomes included the number of in-range versus out-of-range follow-up INR values, the number of extremely out-of-range follow-up INR values (≤ 1.5 or ≥ 4.0), major and clinically relevant non-major (CRNM) bleeding as defined according to the ISTH criteria, and thromboembolic event rates during the INR testing interval for eligible patients who did and did not receive an extended INR testing interval [8, 9] . All clinical events (bleeding and thromboembolic) were chart-abstracted by the trained abstractors and randomly audited by the MAQI 2 coordinating center to ensure accuracy.
Statistical analysis
A chi-square test was used to assess the association between an extended INR testing interval and clinical variables, including age, gender, HAS-BLED score, and indications [10] . Table 2 ).
The overall percentage of eligible patients who had an extended INR testing interval increased from 41.8% in the first quarter of 2014 to 69.3% in the fourth quarter of 2016 (P < 0.0001 for trend; Fig. 1 ). There was significant heterogeneity between centers with regard to the rate of extended INR interval testing utilization (Fig. S1) .
The median length of time between INR draws was 42 days (interquartile range [IQR] 42-55 days) for patients who had an extended INR testing interval. The median length of time between INR draws was 28 days (IQR 21-29 days) for patients who were eligible for an extended INR testing interval, but were not offered one (P < 0.0001).
The numbers of subsequent out-of-range follow-up INR values (first INR after the extended testing interval) were similar between eligible patients who did and did not have an extended INR testing interval ( Table 3 (Table 3 ). There were no documented thromboembolic events in either group.
Discussion
We have demonstrated the ability to safely and effectively implement a policy allowing for extended INR testing intervals in stable warfarin patients across six diverse anticoagulation clinics. Implementation increased during the study period to include > 85% of eligible patients being offered at least one extended INR testing interval. Most importantly, there were no significant differences in out-of-range and extreme follow-up INR values between patients who did and did not have an extended INR testing interval. However, out-of-range INR values may be more frequent in patients who go ≥8 weeks between INR tests than in patients with shorter testing intervals. Finally, the overall numbers of clinical adverse events were low, with lower rates of CRNM bleeding events and ED visits in the two groups. Perhaps in contrast to common assumptions, the percentage of patients with a CRNM bleeding event was higher in the cohort of patients who did not have an extended INR testing interval than in the cohort of patients who had their INR testing interval extended. In the randomized trial on which this intervention was based, Schulman et al. randomized 250 patients with 6 months of stable warfarin dosing to a standard 4-week INR testing interval or an extended 12-week testing interval [3] . With more than twice the number of patients as the Schulman study, we were able to demonstrate similar safety and efficacy, albeit with a shorter amount of time between the INR tests in the extended group. Each of our anticoagulation clinics elected to use a shorter period for the extended INR testing interval (6-8 weeks) . Two primary factors led to this decision. First, very few patients across the six anticoagulation clinics would have qualified as stable if the 6-month stable warfarin dose requirement that was used in the randomized trial had been implemented in our clinics. By shortening the required time for patients to be deemed stable, we were able to include many more patients. However, that decision made most of the clinic staff and physician directors feel that a full 12 weeks between INR tests would not be appropriate. Therefore, each clinic decided to begin with a 6-8-week maximum interval. After reviewing the safety data, many of these clinics have begun to extend the INR testing interval to 8-10 weeks since 2015, with continued safety monitoring. Our data suggest that, for many patients, a 5-8-week period may produce better outcomes than longer intervals, at least with regard to the next INR value.
As this represents practice-based implementation, there was significant heterogeneity between sites (Fig. 1) . One site in particular (clinic 3) had stable low rates of extended INR testing utilization during the first few quarters. In April 2014, the research team presented the ongoing data from the other five centers at a monthly anticoagulation staff meeting. This presentation included data on the frequency of extended INR testing interval utilization and the safety outcomes from those sites. Many of the nursing and pharmacist staff expressed their concerns about the safety and lack of willingness to trust a single randomized trial in their patient population before the presentation [11] . However, after the presentation, implementation of this intervention improved, with > 45% of eligible patients at that center having an extended INR testing interval by the fourth quarter of 2014.
In addition to reducing the burden of frequent blood draws on patients, implementing an extended INR testing interval may also help to reduce overall healthcare costs and reduce anticoagulation clinic workload. Using a payment cost of $5.37 per INR test, we estimate that the six participating anticoagulation clinics saved more than $400 000 over a 4-year time period because of this implementation effort. In other recent work, we measured a median of 2.9 min (IQR 1.8-5.8 min) for anticoagulation staff to manage an in-range INR value [12] . With avoidance of these INR tests, the available time for anticoagulation staff to spend with patients at greater need of their services can quickly add up.
Our study has a number of important strengths. First, it provides the first published data on the implementation, safety and efficacy of an extended INR testing interval for stable warfarin patients following the single randomized trial published in 2011. Second, it demonstrates the unique challenges of and subsequent successes with the implementation of randomized clinical evidence in everyday practice among a diverse set of anticoagulation clinics. However, certain limitations must be acknowledged. First, our protocols for determining warfarin stability and the maximal INR testing interval were somewhat individualized for each center, and differed from those of the randomized trial on which they are based. However, this represents the practice-based implementation and dissemination of randomized trials. Second, our sample size and number of hard clinical events (e.g. major bleeding and thromboembolic events) were too small to allow firm conclusions to be drawn about the association between an extended INR testing interval and these risks. However, the intermediate outcomes of out-of-range and extreme follow-up INR values are very reassuring. Finally, as this analysis represents observational data, we cannot account for potential bias in the patients who did and did not receive an extended INR testing interval. This includes the instincts of an anticoagulation nurse or pharmacist regarding the safety of extending the INR testing interval for a given patient at a given time. However, as this article is intended to describe the implementation reach and effectiveness of known clinical evidence, these biases highlight the challenges that nurses, pharmacists, clinicians and patients must encounter when trying to implement the randomized trial evidence base. It also highlights the potential success and impact that such a policy can have for stable warfarin-treated patients.
In conclusion, we have demonstrated a successful ongoing implementation effort to extend the INR testing interval for stable warfarin patients. Although further progress remains to be made, over half of all eligible patients are recommended for INR testing no more frequently than every 6 weeks, reducing the burden of frequent blood draws. Further efforts are needed to understand the remaining barriers to more complete implementation and adoption of this evidence base. 
